Three BC research teams have received Movember Discovery Grants from the Movember Foundation through Prostate Cancer Canada to build on innovative prostate cancer research projects covering a wide breadth of areas.
Dr Alexander Wyatt, Dr Kim Chi, and their team at the University of British Columbia and Vancouver Coastal Health Research Institute will build on their previous work, analyzing DNA from the blood of patients with advanced prostate cancer. They will determine whether the presence or absence of particular genetic changes can predict if and how patients will respond to treatment to help explain why some cancers are drug resistant, and they will guide the development of a test to help select the best treatment for individual patients.
Dr Cheryl Helgason and her team at the BC Cancer Agency in Victoria is focused on RNA that is not able to produce proteins. Dr Helgason’s team discovered that one such RNA (PCAT18) is present at much higher levels in metastatic prostate cancer, and they will assess this RNA to determine whether disabling it blocks the growth of cancer cells, and whether measuring its presence can be used as a diagnostic tool to complement or replace PSA testing.
Dr Julian Lum, Dr Brad Nelson, and their team at the BC Cancer Agency in Victoria will focus on immunotherapy. The treatment for high-risk cases of prostate cancer is often hormone therapy paired with radiation treatment. The team has discovered that 30% of patients treated this way develop an immune response, and 71% of these patients have a shorter time-to-cancer relapse. This finding suggests that hormone therapy and radiation can lead to detrimental immune responses that may result in an earlier relapse. The team will explore how and why hormone and radiation therapy cause detrimental immune responses and test immunotherapeutic approaches that are able to reverse this outcome.
Eleven additional research teams working out of a number of universities and health care institutions across Canada also received the grant. Each grant is worth up to $200 000.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org